Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan.
Department of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, Kobe, Japan.
Cancer Med. 2022 Oct;11(19):3593-3601. doi: 10.1002/cam4.4741. Epub 2022 Apr 7.
The goal of this multicenter retrospective study of patients with head and neck malignancies was to evaluate the efficacy and safety of carbon-ion (C-ion) radiotherapy (RT) after photon RT.
We enrolled 56 patients with head and neck malignancies who underwent re-irradiation (re-RT) using C-ions between November 2003 and March 2019, treated previously with photon RT. The tumors at re-RT were located in the sinonasal cavities (n = 20, 35.7%), skull base (n = 12, 21.4%), and orbit (n = 7, 12.5%). The tumors at the initial RT were located in the sinonasal cavities (n = 13, 23.2%), skull base (n = 9, 16.1%), and orbit (n = 9, 16.1%). The median period between the initial RT and re-RT was 41 (4-568) months. The most common histology of re-RT was squamous cell carcinoma (n = 11, 19.6%). The most commonly used protocol was 57.6 Gy (relative biological effectiveness) in 16 fractions (n = 23, 41.1%). Surgery preceded re-RT in three patients (5.4%). One patient with malignant melanoma received concurrent chemotherapy.
The 2-year local control, progression-free survival, and overall survival rates were 66.5%, 36.9%, and 67.9%, respectively. The median follow-up time was 28 months. Two patients (3.6%) developed grade ≥ 3 acute toxicities, and 14 (25.0%) developed grade ≥ 3 late toxicities. A single patient had confirmed grade 5 dermatitis with infection.
Re-RT using C-ions for head and neck malignancies after photon RT is an effective treatment with tolerable toxicity.
本项多中心回顾性研究纳入了 56 例头颈部恶性肿瘤患者,这些患者在先前接受光子放射治疗(RT)后,采用碳离子(C 离子)再次进行放射治疗(re-RT),旨在评估 C 离子 RT 的疗效和安全性。
我们纳入了 56 例先前接受光子 RT 治疗后,再次采用 C 离子进行 re-RT 的头颈部恶性肿瘤患者。在 re-RT 时,肿瘤位于鼻腔鼻窦(n=20,35.7%)、颅底(n=12,21.4%)和眼眶(n=7,12.5%)。在初始 RT 时,肿瘤位于鼻腔鼻窦(n=13,23.2%)、颅底(n=9,16.1%)和眼眶(n=9,16.1%)。初始 RT 与 re-RT 之间的中位时间为 41(4-568)个月。re-RT 最常见的组织学类型是鳞状细胞癌(n=11,19.6%)。最常使用的方案是 57.6 Gy(相对生物效应),16 次分割(n=23,41.1%)。3 例患者(5.4%)在 re-RT 前行手术。1 例恶性黑色素瘤患者接受了同期化疗。
2 年局部控制率、无进展生存率和总生存率分别为 66.5%、36.9%和 67.9%。中位随访时间为 28 个月。2 例患者(3.6%)发生 3 级及以上急性毒性,14 例患者(25.0%)发生 3 级及以上晚期毒性。1 例患者发生了确诊的 5 级放射性皮炎伴感染。
光子 RT 后采用 C 离子再次进行头颈部恶性肿瘤的 re-RT 是一种有效且毒性可耐受的治疗方法。